ClinicaliQ Trial Snapshot
- Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH Trial — Recruiting • Non-phase study • Cardiology / Cardiovascular • NCT07120776.
- What is being tested: The PEACH trial uses positron emission tomography (PET) imaging to evaluate whether Camzyos (mavacamten), a cardiac myosin inhibitor, reduces myocardial ischaemia in patients with hypertrophic obstructive cardiomyopathy (HOCM) by alleviating left ventricular outflow tract obstruction.
- Patient eligibility overview: The trial enrolls patients with symptomatic HOCM who experience chest pain and other limiting symptoms related to LVOT obstruction, representing the population most likely to benefit from pharmacological intervention.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Hypertrophic obstructive cardiomyopathy (HOCM) is a heritable heart condition that leads to the thickening of the heart muscle and causes obstruction of blood flow, impeding it's ejection from the heart (LVOT obstruction). Often individuals with HOCM suffer from chest pain and shortness of breath due to lack of oxygen supply (ischaemia) to the heart muscle in the absence of blockages in the coronary arteries. Despite proven advances in treatment of LVOT obstruction with the novel medication Camzyos (Mavacamten), there is a limited understanding of its effect on myocardial ischaemia. This…
Eligibility Snapshot
- : 1. Written informed consent. 2. Aged 18 and over. 3. Confirmed diagnosis of Hypertrophic Obstructive Cardiomyopathy (HOCM) based on diagnostic criteria, such as unexplained left ventricular hypertrophy with a maximal wall thickness ≥15 mm in the absence of uncontrolled hypertension, valvular heart disease, or HCM phenocopies such as amyloidosis and storage disorders, and presence of either a resting or provoked peak left ventricular outflow tract (LVOT) gradient ≥30 mmHg. 4. Symptoms suggestive of myocardial ischaemia (chest pain, shortness of breath on exertion) with a clinical indication for Rb-PET. 5. Eligible for Mavacamten treatment according to standard clinical guidelines. [see: https://www.nice.org.uk/guidance/ta913/chapter/1-Recommendations]. Mavacamten is part of participants' regular clinical treatment and is not being supplied, administered, or influenced by the study in any way. 6. PET-CT performed for clinical reasons at any time in the preceding 18 months if reported as abnormal.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.